덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 100+25+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 125+31,25+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 150+37,5+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 200+50+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 50+12,5+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 75+18,75+200 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - carbidopa, entacapon, levodopa - filmovertrukne tabletter - 175+43,75+200 mg

덴마크 - 덴마크어 - Ecolab

ecolab deutschland gmbh -

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

casen recordati, s.l. - dinatriumphosphat, phosphorsyre, koncentreret - oral opløsning

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiske midler - forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically ustabile pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.